RedHill Biopharma (RDHL) Operating Income: 2009-2024
Historic Operating Income for RedHill Biopharma (RDHL) over the last 16 years, with Dec 2024 value amounting to -$14.6 million.
- RedHill Biopharma's Operating Income rose 226.72% to $53.8 million in Q2 2023 from the same period last year, while for Jun 2023 it was -$44.0 million, marking a year-over-year increase of 70.69%. This contributed to the annual value of -$14.6 million for FY2024, which is 215.68% down from last year.
- Per RedHill Biopharma's latest filing, its Operating Income stood at -$14.6 million for FY2024, which was down 215.68% from $12.6 million recorded in FY2023.
- RedHill Biopharma's 5-year Operating Income high stood at $63.7 million for FY2020, and its period low was -$81.1 million during FY2021.
- Its 3-year average for Operating Income is -$14.9 million, with a median of -$14.6 million in 2024.
- As far as peak fluctuations go, RedHill Biopharma's Operating Income crashed by 227.40% in 2021, and later surged by 129.48% in 2023.
- Yearly analysis of 5 years shows RedHill Biopharma's Operating Income stood at $63.7 million in 2020, then tumbled by 227.40% to -$81.1 million in 2021, then surged by 47.19% to -$42.8 million in 2022, then soared by 129.48% to $12.6 million in 2023, then slumped by 215.68% to -$14.6 million in 2024.